Bristol Myers Squibb stock rocketed Monday after AbbVie's experimental schizophrenia treatment failed in a pair of midstage studies.
TSM stock fell Monday after the U.S. ordered Taiwan Semiconductor Manufacturing to halt shipments of advanced chips to China.
The biomarker assay can be used potentially to enrich clinical trials and monitor patients' disease activity and treatment response.